BioGend Therapeutics Co., Ltd. (TPEX:6733)
Taiwan · Delayed Price · Currency is TWD 36.80
+0.30 (0.82%)
Feb 11, 2026, 1:30 PM CST
BioGend Therapeutics Market Cap
BioGend Therapeutics has a market cap or net worth of 4.54 billion as of February 10, 2026. Its market cap has increased by 10.70% in one year.
Market Cap
4.54B
Enterprise Value
4.03B
Revenue
212.43M
Ranking
n/a
PE Ratio
n/a
Stock Price
36.80
Market Cap Chart
Since June 18, 2019, BioGend Therapeutics's market cap has increased from 2.71B to 4.54B, an increase of 67.23%. That is a compound annual growth rate of 8.03%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 10, 2026 | 4.54B | -4.95% |
| Dec 31, 2025 | 4.78B | 14.21% |
| Dec 31, 2024 | 4.18B | -11.18% |
| Dec 29, 2023 | 4.71B | 109.50% |
| Dec 30, 2022 | 2.25B | -18.50% |
| Dec 30, 2021 | 2.76B | -22.86% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Jun 18, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Locus Cell | 5.40B |
| Panion & Bf Biotech | 5.34B |
| UnicoCell Biomed | 5.27B |
| Steminent Biotherapeutics | 5.19B |
| AnnJi Pharmaceutical | 4.77B |
| Senhwa Biosciences | 4.66B |
| Medigen Biotechnology | 4.40B |
| ACRO Biomedical | 4.27B |